Display options
Cite
Pronzato P, Vigani A, Vaira F, et al. Interleukin-2 and interferon alpha 2 combination. Oncol Rep. 1996;3(6):1137-9doi: 10.3892/or.3.6.1137.
Pronzato, P., Vigani, A., Vaira, F., Tani, F., & Vanoli, M. (1996). Interleukin-2 and interferon alpha 2 combination. Oncology reports, 3(6), 1137-9. https://doi.org/10.3892/or.3.6.1137
Pronzato, P, et al. "Interleukin-2 and interferon alpha 2 combination." Oncology reports vol. 3,6 (1996): 1137-9. doi: https://doi.org/10.3892/or.3.6.1137
Pronzato P, Vigani A, Vaira F, Tani F, Vanoli M. Interleukin-2 and interferon alpha 2 combination. Oncol Rep. 1996 Nov;3(6):1137-9. doi: 10.3892/or.3.6.1137. PMID: 21594525.
Copy Download .nbib Format: NLM
Share it on

Oncol Rep. 1996 Nov;3(6):1137-9. doi: 10.3892/or.3.6.1137.

Interleukin-2 and interferon alpha 2 combination.

Oncology reports

P Pronzato, A Vigani, F Vaira, F Tani, M Vanoli

Affiliations

  1. OSPED S ANDREA,DEPT UROL,I-19100 LA SPEZIA,ITALY. OSPED S ANDREA,DEPT RADIOTHERAPY,I-19100 LA SPEZIA,ITALY.

PMID: 21594525 DOI: 10.3892/or.3.6.1137

Abstract

We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon alpha 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.

Publication Types